-
Mashup Score: 79Latest News - Daily Reporter - 8 month(s) ago
BRCA mutations are associated with worse treatment outcomes in mCRPC
Source: dailyreporter.esmo.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 76Latest News - Daily Reporter - 8 month(s) ago
BRCA mutations are associated with worse treatment outcomes in mCRPC
Source: dailyreporter.esmo.orgCategories: General Medicine News, Hem/OncsTweet-
https://t.co/c6CHqNEilv https://t.co/N4RzQBojSZ
-
-
Mashup Score: 109ctDNA% prediction - Metastatic castration-resistant prostate cancer - 8 month(s) ago
Fill in a patient’s clinical information and press the button labeled “Predict ctDNA%”. All fields are optional but the more you provide the more accurate the results will be. The website predicts the patient’s plasma circulating tumor DNA (ctDNA) fraction, as well as the probability of the patient having a ctDNA fraction greater than 2%. Commercial ctDNA tests are now widely used to identify patients for biomarker-direct ed therapies (e.g. PARP inhibitors in BRCA2-defective cancers), but these tests are
Source: ctdna.orgCategories: General Medicine News, Hem/OncsTweet-
📢A really easy tool to estimate ctDNA fraction in the clinic, isn’t it cool?? https://t.co/2ux1WW48dW Congratulations and big thank you @ResearchWyatt https://t.co/8GDjmbrBaH https://t.co/E73ZZwNxJZ
-
-
Mashup Score: 108ctDNA% prediction - Metastatic castration-resistant prostate cancer - 8 month(s) ago
Fill in a patient’s clinical information and press the button labeled “Predict ctDNA%”. All fields are optional but the more you provide the more accurate the results will be. The website predicts the patient’s plasma circulating tumor DNA (ctDNA) fraction, as well as the probability of the patient having a ctDNA fraction greater than 2%. Commercial ctDNA tests are now widely used to identify patients for biomarker-direct ed therapies (e.g. PARP inhibitors in BRCA2-defective cancers), but these tests are
Source: ctdna.orgCategories: General Medicine News, Hem/OncsTweet-
📢A really easy tool to estimate ctDNA fraction in the clinic, isn’t it cool?? https://t.co/2ux1WW48dW Congratulations and big thank you @ResearchWyatt https://t.co/8GDjmbrBaH https://t.co/E73ZZwNxJZ
-
-
Mashup Score: 15HOPE PRĂ“STATA - Profesionales - 9 month(s) ago
ÂżCĂłmo? A la hora de registrarse en HOPE PRĂ“STATA, tu paciente podrá incluir tu correo electrĂłnico como referencia, para que obtengas los resultados de sus análisis genĂ©ticos y seas invitado/a a participar en el Molecular Advisory Board (MAB). Si lo incluye, recibirás un email para autorizar tu implicaciĂłn en el proceso. …
Source: hopeprostata.comCategories: General Medicine News, Hem/OncsTweet-
@quimmateo @JoanJocarles @_SOLTI https://t.co/ZbasjOwXIO https://t.co/FJcLjd2Z8H
-
-
Mashup Score: 42ESMO Manifesto - 9 month(s) ago
The ESMO Manifesto represents the Society’s commitment to support European institutions as well as national decision-makers
Source: www.esmo.orgCategories: General Medicine News, Hem/OncsTweet-
By 2040, cancer cases are projected to increase by 20% in Europe. There will be over 12 million cancer survivors. A real change is needed. On #WorldCancerDay2024 ESMO has launched its Manifesto “For a Healthier Europe” https://t.co/fq6ctzlSYR. @myESMO
-
-
Mashup Score: 38Development of PARP inhibitors in advanced prostate cancer - Maria Teresa Bourlon, Paola Valdez, Elena Castro, 2024 - 10 month(s) ago
The relatively high prevalence of alterations in the homologous recombination repair (HRR) pathway described in advanced prostate cancer provides a unique oppor…
Source: journals.sagepub.comCategories: General Medicine News, Hem/OncsTweet-
Happy to share our review on the development of PARPi for prostate cancer, by @BourlonMaite at @TAMedOncol https://t.co/JI01esAhHk
-
-
Mashup Score: 3El tiempo | Columna - 10 month(s) ago
El tiempo no existe. El tiempo sĂłlo son las cosas que te pasan, por eso pasa tan deprisa cuando a uno ya no le pasa nada. DespuĂ©s de Reyes, un dĂa not
Source: elpais.comCategories: General Medicine News, Hem/OncsTweet-
Como en este texto de Manuel Vicente, os deseo un 2024 lleno de dĂas distintos, de felices sobresaltos, de pasiones nuevas... como cuando Ă©ramos niños. https://t.co/t9ABMEr2Le a travĂ©s de @el_pais
-
-
Mashup Score: 11COMING SOON! The European Urology Oncology podcast - 11 month(s) ago
Dr Renu Eapen and Prof Morgan Roupret tell us about the European Urology Oncology Podcast, coming soon!Also available as a classic audio podcast in all the u…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
RT @MRoupret: Stay tuned !!! 📻 https://t.co/qIfGJFSaj3 soon @EurUrolOncol #podcast will be live and emphasizing our best authors and public…
-
-
Mashup Score: 27Laying the foundations for next-generation precision oncology - 11 month(s) ago
ESMO initiatives highlight the need for closing the gap between fast cancer research and a lack of accessibility to treatments in the real world
Source: dailyreporter.esmo.orgCategories: General Medicine News, Hem/OncsTweet-
The urgent need to close the gap between groundbreaking presentations at congresses with potentially practice-changing results and our clinics, full of patients unlikely to benefit from these advances in the short-term. @myESMO @Seo https://t.co/MBN6kv8lVF
-
https://t.co/c6CHqNEilv https://t.co/N4RzQBojSZ